Studying genetic polymorphism and MASP-2 serum levels in patients with ovarian cancer, Swierzko et al. (9) concluded that the expression of MBL and MASP-2 is altered in ovarian cancer, possibly indicating involvement of the lectin pathway of complement in the disease. The gene discussed is MASP2; the disease is ovarian carcinoma.